Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-06-07 AGM Information
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and contains detailed agenda items for the AGM of CStone Pharmaceuticals, including re-election of directors, approval of financial statements, authorization of share issuance and buy-back mandates, and other shareholder resolutions. It is a notice announcing the upcoming AGM meeting and the matters to be discussed and voted on. There is no actual financial data or report content included, only the notice and agenda for the meeting. The document length is about 14,840 characters, which is consistent with a detailed notice but not a full report. According to the classification rules, a notice of AGM with agenda and resolutions is classified as AGM Information (AGM-R).
2022-06-07 English
FORM OF PROXY FOR ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a Form of Proxy for an Annual General Meeting (AGM) of CStone Pharmaceuticals. It includes instructions for shareholders to appoint proxies to vote on various resolutions at the AGM, including receiving the audited financial statements, re-electing directors, appointing auditors, and granting mandates related to shares. The content is clearly related to the AGM process and voting, not the actual AGM presentation materials or the full annual report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms and voting instructions.
2022-06-07 English
PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a circular to shareholders of CStone Pharmaceuticals regarding proposals for general mandates to issue and buy back shares, re-election of retiring directors, re-appointment of auditor, and notice of the Annual General Meeting (AGM). It includes detailed information about the AGM, proxy forms, precautionary measures, and explanatory statements related to share issuance and buy-back mandates. The document is clearly intended to inform shareholders about the AGM and related proposals, including the notice of the AGM itself. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document is lengthy (15,000 characters) and contains substantive content related to the AGM, not just a brief announcement or proxy solicitation. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-06-07 English
2021 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2021 Annual Report' and contains detailed sections typical of an annual report, including corporate information, financial highlights, business highlights, chairman's statement, management discussion and analysis, directors and senior management, corporate governance report, independent auditor's report, consolidated financial statements, and notes. The content includes comprehensive financial data for the year ended December 31, 2021, and discusses business achievements and strategic developments over the year. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-06-07 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form dated 7 June 2022, reporting dealings in shares of Yankuang Energy Group Company Limited. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is a disclosure of securities dealings related to a possible offer. The content is focused on share transactions by a connected party (CICC Financial Trading Limited) and details of derivative contracts closed out. There is no financial report, earnings data, or management discussion. The document is a notification of insider or related party share dealings, which aligns with the definition of Director's Dealing filings (DIRS). The document length is short and specific to share transactions by a related party, not a full report or announcement of a report publication. Therefore, the correct classification is DIRS with high confidence.
2022-06-07 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It details transactions by CICC Financial Trading Limited, including purchase and sale of shares, with specific dates, quantities, and prices. The document references Rule 22 of the Hong Kong Code on Takeovers and Mergers, which relates to disclosure of share dealings by parties connected to takeover offers. This type of document is a notification of insider or director-related share transactions rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary. Therefore, it fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives or related parties.
2022-06-07 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.